Biocompatibles wins IOM3 award for DC Bead technology

Polymer-based engineering solution deprives cancer cells of nutrients they need to survive

Biocompatibles UK, a medical technology company involved in drug device combination products, has won an award for the development of an innovative cancer product.

The Farnham, Surrey based firm received the Institute of Materials, Minerals and Mining (IOM3) award for Polymers in the Service of Mankind for its DC Bead technology from HRH The Prince Philip, in a ceremony at Buckingham Palace.

DC Bead is a polymer-based engineering solution that ultimately deprives cancer of the nutrients and oxygen that enable it to spread. It is used in a procedure called Transarterial Chemoembolisation (TACE), a minimally invasive medical procedure to restrict a tumour's blood supply. TACE has been used extensively to delay the progression of hepatocellular carcinoma (HCC), a type of liver cancer.

Biocompatibles UK’s main aim is to deliver products that are safe to use, economically viable, with clear clinical advantages. The firm's products use specialised polymer technology engineered to allow ease of delivery to blood vessels of tumours combined with controlled drug delivery capability. It is a pioneer in the use of drug-eluting beads to treat cancer.

Biocompatibles UK Ltd has been part of BTG International group company since 2008.

The Prince Philip award was established in 1973 and is awarded biennually (subject to sufficient merit).

You may also like

Pharmaceutical

CPHI Frankfurt 2025 to welcome more than 60,000 pharma professionals with expanded focus on innovation and sustainability

Returning to Germany from 28-30 October, CPHI Frankfurt 2025 will unite the global pharmaceutical supply chain with more than 2000 exhibitors, six content theatres and new feature zones
Manufacturing

Continuous innovation: redefining the future of pharmaceutical manufacturing

In an industry in which reliability is paramount and change can be slow, GEA has consistently proven that innovation and stability go hand in hand. Almost two decades ago, GEA introduced the first ConsiGma® continuous manufacturing (CM) system to the pharmaceutical market — a pioneering move that helped to reshape how oral solid dosage (OSD) forms are developed and produced
Packaging

Intranasal GLP-1 medication from Orexo shows positive results in preclinical trial

Orexo's AmorphOX technology had positive results when compared against oral and injectable formulations in the study
Drug Delivery

Drug delivery evolution: pharma breakthroughs drive nasal spray market towards $59.4bn

Dr Steve Ward-Smith at Malvern Panalytical shares how advanced particle analysis is fuelling rapid growth in the nasal spray market
Drug Delivery

The SCIEX BioPhase 8800 uses native fluorescence detection for protein-based CE assays

SCIEX, a global leader in life science analytical technologies, launches new native fluorescence detection on the BioPhase 8800 system
Pharmaceutical

Keystone Folding Box Co. unveils Key-Pak Plus

Designed to protect children and empower seniors, it achieves top U.S. safety ratings and meets global accessibility standards
Manufacturing

Quotient Sciences and CPI to accelerate RNA drug development with joint venture

Quotient Sciences and UK technology innovation centre, CPI, have signed a memorandum of understanding (MoU) to form a Joint Venture (JV) aimed at accelerating the development of RNA-based therapies
Subscribe now